Profile data is unavailable for this security.
About the company
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
- Revenue in USD (TTM)35.19m
- Net income in USD-86.45m
- Incorporated2015
- Employees116.00
- LocationFoghorn Therapeutics Inc.500 Technology Square, Suite 700CAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 586-3100
- Fax+1 (302) 655-5049
- Websitehttps://foghorntx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compass Pathways PLC (ADR) | 0.00 | -139.21m | 499.23m | 186.00 | -- | 2.24 | -- | -- | -2.30 | -2.30 | 0.00 | 3.31 | 0.00 | -- | -- | 0.00 | -57.01 | -40.85 | -61.38 | -44.48 | -- | -- | -- | -- | -- | -52.52 | 0.1151 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Entrada Therapeutics Inc | 239.40m | 104.44m | 507.77m | 168.00 | 5.07 | 1.30 | 5.17 | 2.33 | 2.96 | 2.96 | 6.92 | 11.57 | 0.445 | -- | 41.93 | 1,505,642.00 | 19.41 | -- | 24.17 | -- | -- | -- | 43.63 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
| Altimmune Inc | 409.00k | -101.35m | 528.06m | 59.00 | -- | 3.53 | -- | 1,315.42 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Foghorn Therapeutics Inc. | 35.19m | -86.45m | 528.94m | 116.00 | -- | -- | -- | 15.21 | -1.95 | -1.95 | 0.7895 | -0.2589 | 0.1053 | -- | -- | 303,319.00 | -25.88 | -31.35 | -30.84 | -35.69 | -- | -- | -245.69 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Eliem Therapeutics Inc | 0.00 | -64.20m | 535.14m | 9.00 | -- | 2.49 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Neurogene Inc | 925.00k | -55.44m | 536.64m | 91.00 | -- | 3.48 | -- | 583.80 | -4.93 | -4.93 | 0.0748 | 11.93 | 0.0068 | -- | -- | 10,164.83 | -40.49 | -32.70 | -43.33 | -34.73 | -- | -- | -5,993.62 | -- | -- | -- | 0.0007 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Tourmaline Bio Inc | 0.00 | -35.69m | 538.47m | 44.00 | -- | 1.71 | -- | -- | -2.54 | -2.54 | 0.00 | 13.19 | 0.00 | -- | -- | 0.00 | -14.16 | -- | -14.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| OmniAB Inc | 21.71m | -62.38m | 544.73m | 106.00 | -- | 1.90 | -- | 25.74 | -0.6204 | -0.6204 | 0.2159 | 2.49 | 0.0585 | -- | 2.80 | 204,849.10 | -16.80 | -- | -17.72 | -- | -- | -- | -287.29 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Alector Inc | 55.28m | -160.66m | 548.89m | 245.00 | -- | 3.97 | -- | 10.81 | -1.81 | -1.81 | 0.6162 | 1.55 | 0.0864 | -- | -- | 226,536.90 | -25.11 | -20.00 | -32.15 | -23.81 | -- | -- | -290.66 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Third Harmonic Bio Inc | 0.00 | -32.74m | 554.82m | 42.00 | -- | 2.34 | -- | -- | -0.8204 | -0.8204 | 0.00 | 6.31 | 0.00 | -- | -- | 0.00 | -11.87 | -- | -12.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 163.87m | -71.96m | 555.72m | 180.00 | -- | 2.20 | -- | 3.47 | -2.68 | -2.68 | 6.11 | 9.56 | 0.40 | -- | 12.19 | 910,366.70 | -17.57 | -19.66 | -22.59 | -24.90 | -- | -- | -43.92 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Celcuity Inc | 0.00 | -82.59m | 555.82m | 55.00 | -- | 3.18 | -- | -- | -2.74 | -2.74 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -37.03 | -37.32 | -39.38 | -39.16 | -- | -- | -- | -- | -- | -- | 0.3525 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Q32 Bio Inc | 0.00 | -65.02m | 559.57m | 41.00 | -- | 16.88 | -- | -- | -16.24 | -16.24 | 0.00 | 2.79 | 0.00 | -- | -- | 0.00 | -31.38 | -34.98 | -36.35 | -37.92 | -- | -- | -- | -971.76 | -- | -- | 0.2725 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
Data as of Sep 19 2024. Currency figures normalised to Foghorn Therapeutics Inc.'s reporting currency: US Dollar USD
36.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 6.38m | 11.54% |
| BVF Partners LPas of 30 Jun 2024 | 5.30m | 9.58% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 2.34m | 4.23% |
| Euclidean Capital LLCas of 30 Jun 2024 | 1.57m | 2.84% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.36m | 2.47% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.02m | 1.85% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 720.72k | 1.30% |
| Driehaus Capital Management LLCas of 30 Jun 2024 | 568.47k | 1.03% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 544.00k | 0.98% |
| Geode Capital Management LLCas of 30 Jun 2024 | 531.11k | 0.96% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
